Vir Biotechnology, Inc. (VIR) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-07

Key Insights

Marianne De Backer, the President and CEO of Vir Biotechnology, Inc., has sold 72,559 shares of the company's common stock, likely to satisfy tax withholding obligations related to the vesting of restricted stock units.
The reporting person also indirectly owns 53,118 shares of Vir Biotechnology through the Ureel-De Backer Family Trust, of which she and her spouse are trustees.
The sale of shares by the CEO, while routine for tax purposes, may be viewed as a neutral signal by investors as it does not represent a discretionary trade.

Want the newest filings?

This analysis covers the filing from 2026-04-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-24

Insider Brent Sabatini, SVP and Chief Accounting Officer, sold 7,711 shares of Vir Biotechnology, Inc. (VIR) on March 23, 2026 at an average price of $9.12 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan that Sabatini had adopted on December 19, 2025, indicating the transaction was pre-planned.
Following the sale, Sabatini continues to hold 61,902 shares of Vir Biotechnology, demonstrating he still maintains a significant equity stake in the company.

Other reports for Vir Biotechnology, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.